The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i> and detectable in clinical samples prior to treatment
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.